about
PG F(2α) Receptor: A Promising Therapeutic Target for Cardiovascular Disease.Clinical options for the reduction of elevated intraocular pressureIntraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytesBimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases.Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride.EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover studyComparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assayTafluprost for glaucoma.In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line.Tafluprost for the reduction of interocular pressure in open angle glaucoma and ocular hypertension.Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomySafety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.A novel convergent synthesis of the antiglaucoma PGF2α analogue bimatoprost.A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients
P2860
Q34186949-4BBB3112-278C-47C3-A0CD-F63B5313F238Q34708267-1A74E98A-2F1D-417B-A6E4-F439DAC4A61FQ35102806-C38C67EE-3A6F-4A0A-B755-727B5BEDA021Q35860207-9F56F0C3-5389-4FB1-9AAE-C129E23E95F2Q35949978-C5714988-04FD-4E60-8CB6-A00A33D1D489Q36940995-A4F6655D-9567-4F21-A296-D8D70F718BB8Q36968704-3F914B12-B512-485F-80AA-73454663725FQ37318278-51911461-8ABC-4E2C-B303-9F7F21F1FA71Q37931967-C6E41FAE-B74C-43E0-9590-4B5EEF6ED6E5Q39993818-F0BBE5EA-7453-42CA-87F4-B9E3BE91678DQ40938971-0966FA0D-4A04-4DAE-B57F-735DA17F89A2Q41072167-B5141F2D-E41B-4464-B2F6-242A0FEC9A42Q41911324-149117E0-C08C-44A0-8F75-8AC8DB4B8F47Q44637557-571B4D24-2236-4FB4-9D05-954C205EC912Q58915054-F6E28293-8879-48CF-AC1D-E0A6469946D3
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Prostanoids in the therapy of glaucoma.
@ast
Prostanoids in the therapy of glaucoma.
@en
type
label
Prostanoids in the therapy of glaucoma.
@ast
Prostanoids in the therapy of glaucoma.
@en
prefLabel
Prostanoids in the therapy of glaucoma.
@ast
Prostanoids in the therapy of glaucoma.
@en
P2093
P2860
P1476
Prostanoids in the therapy of glaucoma.
@en
P2093
Atsushi Shimazaki
Hideaki Hara
Naruhiro Ishida
Noriko Odani-Kawabata
P2860
P356
10.1111/J.1527-3466.2006.00001.X
P577
2006-01-01T00:00:00Z